Attachment A

U.S. Source	Purpose	Amount
Biomedical Advanced	Contract to fund Phase 2 and	Contract Ceiling is
Research and Development	Phase 3 studies and for	\$483,298,520
Authority (BARDA)	process development/scale up	
	for mRNA-1273.	
National Institutes of Health/	Contract related to Phase 1	\$0
Division of Microbiology and	study. Moderna provided	
Infectious Diseases/National	materials and Division of	
Institute of Allergy and	Microbiology and Infectious	
Infectious Diseases	Diseases performed Phase 1	
(NIH/DMID/NIAID)	study.	
National Institutes of Health	Contract related to receipt of	\$0
(NIH)	proteins and plasmids for	
	evaluation and assay	
	development.	
National Institute of Allergy	Contract related to ongoing	\$0
and Infectious Diseases	research collaboration.	
(NIAID)	Amended to include pre-	
	clinical activities related to	
	SARS-CoV2.	